 BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a clinical-stage biopharmaceutical company focused on oncology, announced today updated data from the triple combination arm of the ongoing Phase 2a COMBATKEYNOTE-202 study. The data was delivered today in an oral presentation entitled, A Multi-Center Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 a CXCR4 inhibitor in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma PDAC, at the European Society of Medical Oncology Immuno-Oncology Congress ESMO IO 2019, which is being held December 11-14 in Geneva, Switzerland. The full presentation is available on the Companys website. 